Israeli researchers optimistic about COVID-19 breathalyser test


Cheryl Guttman Krader
Published: Friday, May 29, 2020
[caption id="attachment_20134" align="alignleft" width="590"]
Image by piotrpiotrwojcicki from Pixabay[/caption]
TeraGroup, an Israeli company, is working with the Israeli Ministry of Defense Administration for the Development of Weapons and Technological Infrastructure (MAFAT) to develop a breathalyser test for COVID-19. In a recent television news segment, researchers involved in the project reported that they are making promising progress.
The technology uses terahertz frequencies and generates a result within 60 seconds. Individuals perform the test by taking a deep breath and then exhaling into a tube three times. Presence of the coronavirus within the exhaled breath aerosols is determined based on recognition of its spectral signature.
In addition to its benefits for providing an immediate result and avoiding any laboratory processing, the test has the advantage of eliminating the need for both a skilled individual to obtain the sample and swabs, which have been in limited supply in some areas.
According to one of the researchers, the breathalyser test may also detect the virus within the first four days after initial exposure, which is a window of time when results from polymerase chain reaction testing may be inaccurate.
The developers believe that by identifying people who are not carrying the SARS-CoV-2 virus that causes COVID-19, the test will allow workers to return to their jobs and thereby assist in mobilising the economy. They describe the breathalyser test as “the new thermometer”.
Amir Tirosh MD, PhD, Director of the Endocrine Institute, Sheba Medical Center, Ramat Gan, Israel, said that this project can change how the world copes with the COVID-19 pandemic.
“If we are debating whether to open the economy, how much to open, and how safe will it be, this changes the rules of the game,” said Dr Tirosh.
The terahertz technology was being used for gender detection in avian eggs. It became the focus for developing a diagnostic test for COVID-19 within just a few days after government leaders and representatives from MAFAT decided to begin thinking outside of the box to come up with ideas for fighting the pandemic, including by looking at the potential of technologies that were already available on the market.
The performance of the breathalyser test is being investigated at the Magen David Adom drive-through testing site in Jerusalem. Individuals who arrived for a traditional swab test at that centre were first asked to blow into the breathalyser’s collection tube.

Tags: covid-19 research
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.